Becker's Healthcare September 21, 2022
Noah Schwartz

Artificial intelligence and precision medicine company Tempus is partnering with the Children’s Oncology Group to study genetic testing-directed treatment in pediatric patients with solid tumors and non-Hodgkin lymphomas and histiocytic disorders.

Tempus will provide genomic sequencing technology to up to 300 patients per year between the ages of 12 months and 21 years. Clinicians will have access to Tempus’ xT assay technology to help identify if patients are eligible for the Children’s Oncology Group’s Pediatric MATCH screening trial, according to the Sept....

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), Partnerships, Pharma / Biotech, Physician, Precision Medicine, Provider, Technology, Trends
Related Articles:
STAT+: After AI protein folding, David Baker’s lab identifies millions of smaller drug candidates
Alphabet shares jump 14% on earnings beat, first-ever dividend
Microsoft: Unlocking AI Benefits Will Require Cultural Changes for Enterprises
Zephyr AI Raises $111 Million in Series A Financing
Chatbot answers are all made up. This new tool helps you figure out which ones to trust.

Share This Article